ADHD Trial, Recruiting NCT05354232 Sponsor: Massachusetts General Hospital Condition: ADHD
Back to Adhd

ADHD Trial, Recruiting

NCT05354232
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 to 65 years (both men and women) who are being seen as outpatients (not staying overnight in a hospital)
  • People who have been diagnosed with ADD or ADHD, or who meet the standard medical diagnostic criteria for ADD/ADHD as defined in the DSM-5 (a widely used mental health diagnosis guide)

Who may not be able to join:

  • People for whom the brain stimulation treatment used in this trial (called tDCS) would not be safe, including those with a history of epilepsy, metal implants in the head or neck, brain stimulators, vagus nerve stimulators, a VP shunt (a device that drains fluid from the brain), a pacemaker, or who are pregnant
  • People who are currently dependent on substances such as alcohol or drugs (tobacco is the exception and does not apply here)
  • Women who are pregnant or breastfeeding
  • People who are unable to take part in the testing or assessment activities required by the trial
  • People with pre-existing neurological conditions such as traumatic brain injury, stroke, Parkinson's disease, Alzheimer's disease, or other forms of dementia, or those with serious psychiatric conditions such as bipolar disorder or schizophrenia

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Joan Camprodon, MD, PHD, MPH, MGB: Division of Neuropsychiatry and Neuromodulation

Phone: 6177265348

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 July 2022
Est. completion
1 May 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

P300 Amplitude during Erickson Flanker Task; Global Assessment of Functioning (GAF) Scale; Adult ADHD Self-Report Scale

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov